1. Home
  2. DDOG vs REGN Comparison

DDOG vs REGN Comparison

Compare DDOG & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Datadog Inc.

DDOG

Datadog Inc.

HOLD

Current Price

$260.36

Market Cap

71.2B

Sector

Technology

ML Signal

HOLD

Logo Regeneron Pharmaceuticals Inc.

REGN

Regeneron Pharmaceuticals Inc.

HOLD

Current Price

$654.27

Market Cap

73.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DDOG
REGN
Founded
2010
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
71.2B
73.2B
IPO Year
2019
1995

Fundamental Metrics

Financial Performance
Metric
DDOG
REGN
Price
$260.36
$654.27
Analyst Decision
Strong Buy
Buy
Analyst Count
34
25
Target Price
$180.12
$830.16
AVG Volume (30 Days)
4.5M
996.2K
Earning Date
05-07-2026
04-29-2026
Dividend Yield
N/A
0.55%
EPS Growth
N/A
8.19
EPS
0.15
6.75
Revenue
$3,427,158,000.00
$5,872,227,000.00
Revenue This Year
$22.55
$12.45
Revenue Next Year
$19.45
$10.13
P/E Ratio
$1,735.93
$96.98
Revenue Growth
27.68
20.82
52 Week Low
$98.01
$541.00
52 Week High
$278.71
$821.11

Technical Indicators

Market Signals
Indicator
DDOG
REGN
Relative Strength Index (RSI) 68.96 59.65
Support Level $215.91 $593.21
Resistance Level $278.71 $664.00
Average True Range (ATR) 11.00 14.28
MACD 1.70 6.56
Stochastic Oscillator 81.38 98.89

Price Performance

Historical Comparison
DDOG
REGN

About DDOG Datadog Inc.

Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered via software as a service, enables clients to monitor and analyze their entire information technology infrastructure, from servers to applications and Python scripts. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of applications throughout their businesses to ensure uptime and latency objectives.

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.

Share on Social Networks: